Sweden Builds World-Class Healthcare AI, Then Exports Its Founders

The Best AI Healthcare Lab in the World Has a Leak

A Swedish hospital just proved that one AI system plus one radiologist can obliterate breast screening backlogs. Not in a research paper. Not in a pitch deck. In production, with real patients, right now. This is operational proof that most US health systems, with their 10x budgets, cannot match. Meanwhile, Sifted reports today that Sweden's national AI strategy still won't keep its best founders at home. Let that sink in. We build the proof. Someone else builds the company.

I run HEIMLANDR.IO from Jönköping, not from San Francisco. That is a deliberate choice. But I watch founder after founder in the Swedish AI automation business space get pulled across the Atlantic, not because the technology is better there, but because the capital structure is. And in healthcare AI specifically, this pattern is becoming a national problem.

What Sweden Actually Has (And Why It Matters)

Let me lay this out plainly because most people outside the Nordics do not understand the full picture.

Sweden has a single-payer health system with unified patient records. That means structured, longitudinal, population-level data across millions of people, the kind of dataset that US companies spend years and hundreds of millions trying to assemble through fragmented hospital partnerships. We already have it. It exists. Researchers can access it through ethical review boards that actually function.

Vinnova just announced a Sweden-Canada AI collaboration that is delivering real patient outcomes in Swedish hospitals right now. Not "promising results." Outcomes. Tandem Health, a Swedish company, just acquired Dutch healthcare AI startup Juvoly, consolidating Nordic health-AI talent under a Swedish roof. These are signs of a maturing ecosystem.

And here is the part that genuinely surprised me. Medical Xpress reports that the Swedish public sets a higher bar for AI in healthcare than almost any other population surveyed. This is not skepticism. It is informed demand. Swedes want AI in healthcare. They just want it done properly. That is a feature, not a bug. It means the companies that survive the Swedish market have product-market fit that transfers globally.

Regulatory sandboxes? Sweden has them. The Swedish Medical Products Agency runs frameworks that let you test clinical AI in controlled environments with real regulatory guidance. Try getting that in the US without a two-year FDA conversation and a team of regulatory lawyers billing $800 an hour.

The Leak: Where the Founders Go

So we have the data, the trust, the regulatory access, and the clinical proof points. What we do not have is the ability to keep the people who turn all of this into scaled global companies.

The pattern is painfully predictable. A founder builds something real using Swedish clinical infrastructure. They get traction. Maybe a pilot at Karolinska or Sahlgrenska. Then a US VC shows up with a term sheet that no Swedish or European investor will match. The founder relocates. The IP goes with them. The company reincorporates in Delaware. Swedish taxpayers funded the research, the university, the hospital access, the regulatory sandbox. American shareholders capture the returns.

This is not a new story. But in healthcare AI, it is particularly damaging because the competitive advantage is the data infrastructure. Once a founder leaves, the next founder has to rebuild relationships with the same hospitals, the same ethics boards, the same data custodians. There is no institutional memory being built in the startup ecosystem. It resets every time.

I have talked to founders who left. Most of them did not want to. The decision usually comes down to three things: capital availability, employee stock option taxation, and the sheer gravitational pull of a market where a Series A can be $30M instead of $3M. Sweden's option tax situation has improved since the 2018 reforms, but it is still not competitive with the US or even the UK. For a healthcare AI startup that needs 3-5 years to reach revenue, that matters enormously.

Sweden vs. The World: A Comparative Reality Check

The US has the capital and the market size. It does not have the data infrastructure. American health data is fragmented across thousands of systems, locked behind HIPAA interpretations that vary by hospital counsel, and increasingly weaponized in litigation. Building a clinical AI product in the US means spending half your runway on data access agreements.

The UK has the NHS, which theoretically provides population-level data, but in practice the political sensitivity around NHS data sharing (remember the Palantir debates) makes it unreliable as a foundation for startups. Good luck building a company on data access that could evaporate with the next election cycle.

China has the scale and the state willingness to deploy, but the regulatory opacity and geopolitical isolation make it a closed market. What is built there stays there.

Israel punches above its weight in health-tech but lacks the population-level data that Scandinavian countries have. Their strength is military-to-civilian tech transfer, not clinical data infrastructure.

Sweden, alongside Denmark and Finland, sits in a genuinely unique position. Population-level data. High public trust. Functional regulatory frameworks. Small enough to move fast, sophisticated enough to produce globally transferable products. And yet the commercialization step keeps happening somewhere else.

From Jönköping, I see this with painful clarity. We are not in Stockholm. We are not plugged into the VC circuit. But we build custom AI solutions for clients who need things that work, not things that impress investors at a demo day. The healthcare founders I talk to here do not lack talent or ideas. They lack a domestic capital structure that believes in them past seed stage.

Tandem Health Gets It. Will Anyone Else?

Tandem Health acquiring Juvoly is interesting precisely because it goes against the pattern. A Swedish company buying a Dutch health-AI startup and consolidating in Sweden. That is what it looks like when a Swedish company decides to be the acquirer rather than the acquired. We need more of this.

But Tandem Health is the exception. The default outcome for a high-potential Swedish health-AI company is still acquisition by a US or UK company within 3-5 years of founding. The Sifted coverage makes this painfully clear: Sweden's AI strategy, as currently constructed, is an R&D subsidy program for foreign acquirers.

The policy fixes are not mysterious. They are just politically uncomfortable:

• Make employee stock options tax-competitive with the US and UK, not just "better than they were in 2017."
• Create a dedicated growth-stage fund for health-AI companies. Not a general innovation fund. A fund that understands clinical validation timelines and can write checks north of €10M.
• Build data access agreements that are institutional, not personal. When a founder leaves a hospital collaboration, the next founder should be able to pick up where they left off.
• Stop treating startup policy as a subset of innovation policy. Startups are not research projects. They are businesses that need revenue pathways, not more grants.

Where This Goes: 2-5 Years and the AGI Question

Healthcare is one of the domains where the path toward more capable AI systems has the most direct impact. As foundation models get better at reasoning over medical data, the advantage shifts from "who has the best algorithm" to "who has the best data and the best clinical integration."

Sweden's advantage gets stronger as AI gets more capable. That is the irony. The better the models become, the more valuable Sweden's structured clinical data and trusted deployment environment become. A frontier model fine-tuned on Swedish population health data, deployed in a system where patients consent to AI-assisted care, validated through functional regulatory sandboxes. That is the stack that wins in 2028.

But only if someone builds a company on it that stays in Sweden long enough to scale.

The AI agent development trajectory is particularly relevant here. We are building AI agents at HEIMLANDR for various domains, and I can tell you: the hard part is never the model. It is the integration. The data pipelines. The trust framework. The regulatory compliance layer. Sweden has spent decades building exactly these layers in healthcare. The agent capabilities that are trending right now on GitHub, tools like OpenHands for AI-driven development or ECC for agent performance optimization, these are the scaffolding. The clinical data and the institutional trust are the foundation. Without the foundation, the scaffolding is just scaffolding.

If Sweden does not fix its commercialization pipeline in the next 2-3 years, the window closes. Not because the data becomes less valuable, but because other countries will catch up on regulatory frameworks and data infrastructure. The EU AI Act, for all its flaws, is pushing every member state to build clinical AI governance. Sweden's head start is real, but it is shrinking.

What to Look At

OpenHands (74K+ stars). AI-driven development framework that is increasingly relevant for health-tech teams building clinical AI integrations. If you are a small Swedish team trying to ship fast without US-level headcount, tools like this matter.

Daytona (72K+ stars). Secure infrastructure for running AI-generated code. Healthcare AI demands audit trails and sandboxed execution. Daytona's architecture maps well to clinical deployment requirements where you cannot just run arbitrary model outputs.

Streamlit (44K+ stars). Still the fastest path from model to clinical demonstration app. When you need to show a radiologist what your model does, you are not building a React frontend. You are building a Streamlit app. Every health-AI founder I know has one.

Vinnova's Sweden-Canada AI Collaboration. Watch this closely. International research collaborations that produce clinical outcomes, not just papers, are the template for how Sweden should be structuring its health-AI infrastructure. The question is whether the outcomes stay in Sweden or get commercialized elsewhere.

What Should Builders Actually Do?

If you are a founder in Swedish health-AI: negotiate your data access agreements to be transferable. Make them institutional, not personal. When you raise your next round, talk to Northzone, EQT Ventures, and the new wave of Nordic deep-tech funds before you take the first call from Andreessen Horowitz. Not because US capital is bad, but because the terms will be better if you have a credible domestic alternative.

If you are a CTO evaluating health-AI infrastructure: look at Swedish hospital partnerships. The clinical validation you can get in Sweden in 12 months takes 36 months in the US. That is not an exaggeration. I have seen the timelines.

If you are building SaaS products in healthcare, consider the Nordic market as your proving ground, not your final market. Build for Swedish regulatory standards and you will have a product that ports to the UK, Germany, and eventually the US with less friction than going the other direction.

And if you are a Swedish policymaker reading this: stop writing AI strategies and start fixing option taxation. Your founders are telling you exactly what they need. The question is whether you are listening or just convening another working group.

From Jönköping, Looking Out

I built HEIMLANDR here because I believe you can build world-class technology from a Swedish city that most people outside Scandinavia cannot pronounce. That belief gets tested every time I watch another talented founder relocate to San Francisco because the math does not work here.

Sweden is running one of the most impressive healthcare AI experiments on the planet. The clinical proof points are real. The public trust is real. The data infrastructure is world-class. And we are handing the commercial upside to other countries because we will not fix the three or four structural problems that everyone in the ecosystem already knows about.

This is not a technology problem. It is a decision problem. And decisions are what founders, CEOs, and yes, policymakers, get paid to make.

Make some.

Fredrik Brunnberg is the CEO of HEIMLANDR.IO, building AI and software solutions from Jönköping, Sweden. This is the daily HEIMLANDR briefing. If you found this valuable, share it with someone who builds things.